Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Drug-induced phospholipidosis: Are there functional consequences?
Autore:
Reasor, MJ; Kacew, S;
Indirizzi:
W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Physiol, Morgantown, WV 26506 USA W Virginia Univ Morgantown WV USA 26506 Physiol, Morgantown, WV 26506 USA Univ Ottawa, Sch Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada Univ Ottawa Ottawa ON Canada K1H 8M5 Mol Med, Ottawa, ON K1H 8M5, Canada
Titolo Testata:
EXPERIMENTAL BIOLOGY AND MEDICINE
fascicolo: 9, volume: 226, anno: 2001,
pagine: 825 - 830
SICI:
1535-3702(200110)226:9<825:DPATFC>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
CATIONIC AMPHIPHILIC DRUGS; RAT ALVEOLAR MACROPHAGES; CHLORPHENTERMINE-INDUCED PHOSPHOLIPIDOSIS; AMIODARONE-INDUCED PHOSPHOLIPIDOSIS; LYSOSOMAL PHOSPHOLIPIDOSIS; CELLULAR PHOSPHOLIPIDOSIS; INDUCED NEPHROTOXICITY; PULMONARY TOXICITY; STORAGE; GENTAMICIN;
Keywords:
phospholipidosis; cationic amphiphilic drugs; alveolar macrophages; phagocytosis; amiodarone; lysosomes; rats; mice; phospholipase;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
71
Recensione:
Indirizzi per estratti:
Indirizzo: Reasor, MJ W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Physiol, POB 9229, Morgantown, WV 26506 USA W Virginia Univ POB 9229 Morgantown WV USA 26506 , WV 26506 USA
Citazione:
M.J. Reasor e S. Kacew, "Drug-induced phospholipidosis: Are there functional consequences?", EXP BIOL ME, 226(9), 2001, pp. 825-830

Abstract

Phospholipidosis induced by drugs with a cationic amphiphilic structure isa generalized condition in humans and animals that is characterized by an intracellular accumulation of phospholipids and the concurrent development of concentric lamellar bodies. The primary mechanism responsible for the development of phospholipidosis is an inhibition of lysosomal phospholipase activity by the drugs. While the biochemical and ultrastructural features ofthe condition have been well characterized, much less effort has been directed toward understanding whether the condition has adverse effects on the organism. While there are a few cationic amphiphilic drugs that have been reported to cause phospholipidosis in humans, the principal concern with this condition is in the pharmaceutical industry during preclinical testing. While this class of drugs should technically be referred to as cationic lipophilic, the term cationic amphiphilic is widely used and recognized in thisfield, and for this reason, the terminology cationic amphiphilic drugs (CADs) will be employed in this Minireview. The aim of this Minireview is to provide an evaluation of the state of knowledge on the functional consequences of CAD-induced phospholipidosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 09:10:25